A Novel Treatment for Non-Small Cell Lung Cancer Using Mesothelin-Targeted Immunotoxins
Description of Invention:
Mesothelin is a glycoprotein, whose expression has been largely restricted to mesothelial cells in normal tissues, although epithelial cells of the trachea, tonsil, fallopian tube, and kidney have shown immunoreactivity. Mesothelin has been shown to be expressed in several cancers including pancreatic carcinomas, gastric carcinomas and ovarian carcinomas, and has the potential of being used as a tumor marker and a novel target for the development of new treatments.
The technology relates to the finding that some non-small cell lung cancers (NSCLC) express the antigen mesothelin. Targeting the tumors with antibodies or immunotoxins that specifically bind mesothelin can be a potential new treatment for non-small cell lung cancer. The SSIP immunotoxin and its variants that specifically bind to mesothelin can be used for the treatment of NSCLC.
Applications and Modality:
NSCLC can be treated by targeting mesothelin.
Advantage:
Anti-mesothelin antibodies and immunotoxins are already available and being tested for several cancers.
Development Status:
The technology is in pre-clinical stage of development.
Patent Status:
DHHS Reference No. E-120-2007/0 --
U.S. Provisional Application No. 60/891,923 filed 27 Feb 2007
Licensing Status: This technology is no longer available for licensing.
Collaborative Research Opportunity:
The National Cancer Institute's Laboratory of Molecular Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize anti-mesothelin antibodies and immunotoxins. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Therapeutics-Immunoconjugates-Mab Cancer -Therapeutics-Immunoconjugates-Toxins Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
